<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359462</url>
  </required_header>
  <id_info>
    <org_study_id>156-09-806-01</org_study_id>
    <nct_id>NCT01359462</nct_id>
  </id_info>
  <brief_title>Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis</brief_title>
  <official_title>A Clinical Study of Multiple-dose Pharmacokinetics of Tolvaptan Tablets Administered Orally (15mg Daily) for Consecutively 7 Days in Chinese Patients With Hepatocirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics,&#xD;
      pharmacology, and safety of the drug under fasting condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and&#xD;
      safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in&#xD;
      Chinese adult patients with confirmed Child-Pugh Class B（score 7-9） hepatocirrhosis&#xD;
      (accompanied by ascites).&#xD;
&#xD;
      Trial Design:&#xD;
&#xD;
        1. Open, single-center, multi-dose pharmacokinetics study&#xD;
&#xD;
        2. Study population:&#xD;
&#xD;
           Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis&#xD;
           (accompanied by ascites)&#xD;
&#xD;
        3. Dosage and mode of administration of investigational product:&#xD;
&#xD;
           Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from&#xD;
           day 1 of treatment.&#xD;
&#xD;
        4. Study duration:&#xD;
&#xD;
      Screening: 14 days in maximum; Treatment(s): 7 days; Observation: 1 day&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of tolvaptan and its metabolites DM-4103 and DM-4107</measure>
    <time_frame>blood sample will be collected at predose, 2,4,6,8,12,24 hour of first drug administration and predose of sixth drug administration and predose,2,4,6,8,12,24 hour of seventh drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacological parameter:Serum concentration of sodium and potassium</measure>
    <time_frame>Blood sample will be collected at predose on day1;12,24hour of first dosing;before breakfast on day3 to day6;predose and 12,24hour of seventh dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacological parameter:24-hr urine</measure>
    <time_frame>From day-1 to day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Tolvaptan 15mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolvaptan</intervention_name>
    <description>Drug: tolvaptan&#xD;
tablet, 15mg, Qd, for 7 days.</description>
    <arm_group_label>Tolvaptan 15mg tablet</arm_group_label>
    <other_name>SAMSCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hepatic Cirrhosis with ascites or lower extremities edema&#xD;
&#xD;
          2. Hospitalized patients&#xD;
&#xD;
          3. 18 years old~75 years old&#xD;
&#xD;
          4. Inform Consent Form Signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any of the following diseases, complications or symptoms:&#xD;
&#xD;
               -  Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above);&#xD;
&#xD;
               -  Malignant ascites;&#xD;
&#xD;
               -  Spontaneous bacterial peritonitis;&#xD;
&#xD;
               -  Likely to have gastrointestinal bleeding during the study period;&#xD;
&#xD;
               -  Heart failure (NYHA Note 2 Class Ⅲ andⅣ);&#xD;
&#xD;
               -  Anuria (daily urine output below 100mL);&#xD;
&#xD;
               -  Dysuria induced by urinary tract stenosis, calculus, or tumor.&#xD;
&#xD;
          2. Patients with any of the following history:&#xD;
&#xD;
               -  With gastrointestinal bleeding within 10 days prior to screening;&#xD;
&#xD;
               -  With cerebrovascular accident within 1 month prior to screening;&#xD;
&#xD;
               -  With gout attack within 1 month prior to screening;&#xD;
&#xD;
               -  With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.).&#xD;
&#xD;
          3. Patients whose systolic blood pressure is below 90mmHg during screening;&#xD;
&#xD;
          4. Patients with abnormal values in the following lab examination indicators:&#xD;
&#xD;
             Serum creatinine higher than 2.5 times the upper limit of normal range, serum&#xD;
             Na+&gt;145mmol/L(or higher than the upper limit of normal range), serum K+&gt; 5.5 mmol/L,&#xD;
             uric acid&gt;476µmol/L, child-Pugh score&gt;10&#xD;
&#xD;
          5. Patients ineligible for oral medication&#xD;
&#xD;
          6. Patients in pregnancy or lactation; female of childbearing potential not taking&#xD;
             contraceptive measures;&#xD;
&#xD;
          7. Patients having taken blood products including albumin products within 4 days prior to&#xD;
             application of investigational product;&#xD;
&#xD;
          8. Patients having participated in clinical trials of other drugs within 1 month prior to&#xD;
             screening;&#xD;
&#xD;
          9. Patients used to participate in clinical trials of Tolvaptan and take the said drug;&#xD;
&#xD;
         10. Patients determined by the investigator as illegible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minde Zeng</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ms. Feng Yan</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <keyword>hepatic cirrhosis patients with ascites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

